

I & W

Date: July 7, 2006

I hereby certify that, on the date indicated above, I deposited this paper with identified attachments and/or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 by "First Class Mail" service.

Kim Blum
Name (Print)

Kim Blum
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: DOI et al.)	Examiner: Unassigned
)	
Application Number: 10/580,877)	Group Art Unit: Unassigned
)	
Filed: May 25, 2006)	Confirmation No.: Unassigned
)	
Docket No.: 3190-097)	Customer No.: 33432

For: PROCASPASE-1 ACTIVATION INHIBITOR

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR 1.97(b)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

July 7, 2006

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO/SB/08. Pursuant to the current United States Patent and Trademark Office rules, no copies of U.S. Patents/Patent Application Publications are provided.

This Information Disclosure Statement is being submitted before expiration of the three-month period following filing of the above-captioned application.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO/SB/08 be made of record therein and appear

Information Disclosure Statement
U.S. Patent Application No. 10/580,877


on the first page of any patent to issue therefrom.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in this application and applicant determines that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

It is believed that no fee is required to make this a complete and timely filing. However, if it is determined that a petition or fee is required, the Commissioner is hereby authorized to charge any fee associated with this statement to our Deposit Account No. 50-0925.

Respectfully submitted,



Luke A. Kilyk
Reg. No. 33,251

Atty. Docket No.: 3190-097
KILYK & BOWERSOX, P.L.L.C.
400 Holiday Court, Suite 102
Warrenton, VA 20186
Tel.: (540) 428-1701
Fax: (540) 428-1720
Enclosures: PTO/SB/08 w/24 Documents



Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Application Number	10/580,877
Filing Date	May 25, 2006
First Named Inventor	DOI et al.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	3190-097

[illegible][illegible]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/580,877
Filing Date	May 25, 2006
First Named Inventor	DOI et al.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	3190-097

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city, and/or country where published.	T ²
		DAMIANO, Jason S. et al., "Heterotypic Interactions Among NACHT Domains: Implications for Regulation of Innate Immune Responses", Biochem. J., 2004, Vol. 381, pp. 213-219.	
		YOO, Jin Nam et al., "Nod1, a CARD Protein, Enhances Pro-Interleukin-1 β Processing Through the Interaction with Pro-Caspase-1", Biochemical and Biophysical Research Communications, 2002, Vol. 299, pp. 652-658.	
		OGURA, Yasunori et al., "Nod2, a Nod 1/Apaf-1 Family Member That is Restricted to Monocytes and Activates NF- κ B", The Journal of Biochemistry, 2001, Vol. 276, No. 7, pp. 4812-4818.	
		LEE, Sug Hyung et al., "COP a Caspase Recruitment Domain-Containing Protein and Inhibitor of Caspase-1 Activation Processing", Journal of Biological Chemistry, 2001, Vol. 276, No. 37, pp. 34495-34500.	
		THORNBERRY, Nancy A. et al., "A Novel Heterodimeric Cysteine Protease is Required for Interleukin-1 β Processing in Monocytes", Nature, 1992, Vol. 356, pp. 768-774.	
		CERRETTI, Douglas et al., "Molecular Cloning of the Interleukin-1 β Converting Enzyme", Science, 1992, Vol. 256, pp. 97-100.	
		GHAYUR, Tariq et al., "Caspase-1 Processes IFN- γ -Inducing Factor and Regulates LPS-Induced-IFN- γ Production", Nature, 1997, Vol. 386, pp. 619-623.	
		GU, Yong et al., "Activation of Interferon- γ Inducing Factor Mediated by Interleukin-1 β Converting Enzyme", Science, 1997, Vol. 275, pp. 206-209.	
		WILSON, Keith et al., "Structure and Mechanism of Interleukin-1 β Converting Enzyme", Nature, 1994, Vol. 370, pp. 270-275.	
		SCHUMANN, Ralf et al., "Lipopolysaccharide Activates Caspase-1 (Interleukin-1-Converting Enzyme) in Cultured Monocytic and Endothelial Cells", Blood, 1998, Vol. 91, No. 2, pp. 577-584.	
		THOME, Margot et al., "Identification of CARDIAK, a RIP-like Kinase that Associates with Caspase-1", Current Biology, 1995, Vol. 8, pp. 885-888.	
		GUTIERREZ, Olga et al., "Induction of Nod2 in Myelomonocytic and Intestinal Epithelial Cells Via Nuclear Factor- κ B Activation", Journal of Biological Chemistry, 2002, Vol. 277, No. 44, pp. 41701-41705.	
		BERREBI, D. et al., "Card15 Gene Overexpression on Mononuclear and Epithelial Cells of the Inflamed Crohn's Disease Colon", Gut, 2003, Vol. 52, pp. 840-846.	
		LI, Ping et al., "Mice Deficient in IL-1 β -Converting Enzyme are Defective in Production of Mature IL-1 β and Resistant to Endotoxic Shock", Cell, 1995, Vol. 80, pp. 401-411.	
		KUIDA, Keisuke et al., "Altered Cytokine Export and Apoptosis in Mice Deficient in Interleukin-1 β Converting Enzyme", Science, 1995, Vol. 267, pp. 2000-2003.	
		SIEGMUND, Britta et al., "IL-1 β -Converting Enzyme (Caspase-1) in Intestinal Inflammation", PNAS, 2001, Vol. 98, No. 23, pp. 13249-13254.	
		FIRESTEIN, Gary S., "Evolving Concepts of Rheumatoid Arthritis", Nature, 2003, Vol. 423, pp. 356-361.	
		SIEGMUND, Britta, "Interleukin-1 β Converting Enzyme (Caspase-1) in Intestinal Inflammation", Biochemical Pharmacology, 2002, Vol. 64, pp. 1-8.	
		INOHARA, Naohiro et al., "Nod1, an Apaf-1-like Activator of Caspase-9 and Nuclear Factor- κ B", Journal of Biological Chemistry, 1999, Vol. 274, pp. 14560-14567.	
		CHAMAILLARD, Mathias et al., "Nods, Nalps and Naip: Intracellular Regulators of Bacterial-Induced Inflammation", Cellular Microbiology, 2003, Vol. 5, pp. 581-592.	
		POYET, Jean-Luc et al., "Identification of Ipaf, a Human Caspase-1-Activating Protein Related to Apaf-1", Journal of Biological Chemistry, 2001, Vol. 276, No. 30, pp. 28309-28313.	
		HUMKE, Eric et al., "ICEBERG: A Novel Inhibitor of Interleukin-1 Generation", Cell, 2000, Vol. 103, pp. 99-111.	
		SCHERBERICH, J.E., "Proinflammatory Blood Monocytes: Main Effector and Target Cells in Systemic and Renal Disease", International Journal of Clinical Pharmacology and Therapeutics, 2003, Vol. 41, pp. 459-464.	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.